The European Investment Bank (EIB) will provide €20 million to finance the research, development and innovation (RDI) programme of Galenicum, a pharmaceutical company founded in […]
• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]
….versus a free combination of two existing inhaled treatments in uncontrolled asthma • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a […]
Copyright © 2021 | WordPress Theme by MH Themes